1. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer
   Jisup Kim et al, 2018, Gynecologic Oncology CrossRef
2. Functional genomics: paving the way for more successful cancer immunotherapy
   Reham Ajina et al, 2018 CrossRef
3. The era of immunogenomics/immunopharmacogenomics
   Makda Zewde et al, 2018, J Hum Genet CrossRef
4. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors
   Giuseppe Curigliano, 2018, Seminars in Cancer Biology CrossRef
5. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist
   Tadashi Hosoya et al, 2018, Proc Natl Acad Sci USA CrossRef
6. Clinical significance of the immune microenvironment in ovarian cancer patients
   Lei Yang et al, 2018, Mol. Omics CrossRef
7. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes
   Suzanne Crumley et al, 2018, Mod Pathol CrossRef
8. Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture
   Sachiko Shiba et al, 2019 CrossRef
9. Immunogenomics: steps toward personalized medicines
   Fokhrul Hossain et al, 2020 CrossRef
10. Comprehensive T cell repertoire characterization of non-small cell lung cancer
    Alexandre Reuben et al, 2020, Nat Commun CrossRef
11. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
    Shuang Zhang et al, 2020, BMC Cancer CrossRef
12. Molecular classification of breast cancer using the mRNA expression profiles of immune-related genes
    Juan Mei et al, 2020, Sci Rep CrossRef
13. Biotinylated streptavidin surface coating improves the efficacy of a PLGA microparticle-based cancer vaccine
    Brett Gross et al, 2020, Bioconjugate Chem. CrossRef
14. Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
    Gi‐Hoon Nam et al, 2020, Adv. Mater. CrossRef
15. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
    Maureen L. Drakes et al, 2020, Cancers CrossRef
16. Immunogenomic landscape of gynecologic carcinosarcoma
    Osamu Gotoh et al, 2020, Gynecologic Oncology CrossRef
17. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer
    Tatsuo Matsuda et al, 2018, Clin Cancer Res CrossRef
18. Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data
    Emily F. Davis-Marcisak et al, 2019, Cancer Res CrossRef
19. Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma.
    Bo Xiao et al, 2020, Front Oncol CrossRef
20. Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
    Jacob S. Bowers et al, 2019, Oncol Rev CrossRef
21. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
    Monica Hsiang et al, 2021, Transl Oncol CrossRef
22. The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling
    Lin Xu et al, 2021, Bioengineered CrossRef
23. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
    Reid P. Bissonnette et al, 2021, BMC Cancer CrossRef
24. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
    Juliette Paillet et al, 2021 CrossRef
25. Single-cell transcriptomic landscape identifies the expansion of peripheral blood monocytes as an indicator of HIV-1-TB co-infection
    Qinglong Guo et al, 2022, Cell Insight CrossRef
26. Immunogenomics: a potential approach for precision medicine
    Tahir Hussain et al, 2022 CrossRef
27. Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma
    Li-Peng Pei et al, 2022, Front. Genet. CrossRef
28. Crosstalk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma
    Rui Geng et al, 2022, Cancers CrossRef
29. SPP1 is a biomarker of cervical cancer prognosis and involved in immune infiltration
    Qian Guo et al, 2022 CrossRef
30. Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma
    Jingsong Shan et al, 2022, Computers in Biology and Medicine CrossRef
31. Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment
    Sanaa Nakad Borrego et al, 2022, Cancers CrossRef
32. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
    Qingyang Liu et al, 2022, Oxid Med Cell Longev CrossRef
33. Molecular mechanism of tumor-infiltrating immune cells regulating endometrial carcinoma
    Silu Ding et al, 2024, Genes & Diseases CrossRef
34. TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification
    Lu Miao et al, 2025, PRA CrossRef
35. High FGF18 expression levels predict poor prognosis in endometrial carcinoma patients and promote tumor growth and metastasis
    Zheng-Yao Lei et al, 2025, J Int Med Res CrossRef